# Procter & Gamble Acquires Thorne for $3.8 Billion in Landmark Supplement Consolidation > Procter & Gamble announced a $3.8 billion acquisition of Thorne, a Utah-based premium supplement brand known for third-party testing and clinical-grade formulations. The deal, expected to close in mid-2025, marks a major inflection point in dietary supplement industry consolidation and signals major CPG players are treating high-margin wellness as a core strategic category. **Published:** 2026-08-10T06:47:03.050920+00:00 · **Author:** dietarysupplement.ai · **Category:** Industry [Web version](https://dietarysupplement.ai/news/procter-gamble-acquires-thorne-for-3-8-billion-in-landmark-supplement-consolidat-f5c2fe33/) · [中文](https://dietarysupplement.ai/zh/news/procter-gamble-acquires-thorne-for-3-8-billion-in-landmark-supplement-consolidat-f5c2fe33/) ![Procter & Gamble Acquires Thorne for $3.8 Billion in Landmark Supplement Consolidation](https://dietarysupplement.ai/images/news/procter-gamble-acquires-thorne-for-3-8-billion-in-landmark-supplement-consolidat-f5c2fe33.webp) ## What Happened [Procter & Gamble announced it will acquire Thorne for $3.8 billion](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQET7_2T1LJ8-TTJKT_cjI6mNS9c9wVjFkeCmULm7ay-6W7LSr0poA5za9Jq07L0CW4nv9B9-vf8auwnj-gh9lvhGv2AHYwrIhHTNIHBIPTN0qqq7dE7gHnG5QkV4hdi), according to Nutraceuticals World. The Cincinnati-based consumer goods giant, which owns brands ranging from Crest and Olay to Gillette and Pampers, is deploying significant capital to acquire Thorne's clinical-grade supplement business, including protein powders, micronutrient formulas, and personalized testing services. Thorne, headquartered in Utah, has built its brand on transparency—third-party testing, ingredient purity certifications, and published research on its formulations. The acquisition is expected to close in mid-2025, pending regulatory approval. ## What the Source Says [P&G characterizes the move as a premium wellness play](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNdd3XgymUad900ide9WtMcKbib_XcrNDmWwpkTuybwJoz61FWwO3iBZjtp4KrLtZCj8HapNRBvWzYlQ1jHMn1DkcLICG47gImzbfhF34SaHK8sX1QuPuylJtq), reflecting the company's confidence that clinical-grade, research-backed supplements command higher margins and customer retention than commodity vitamin products, according to NutraIngredients-USA. Thorne serves over 500,000 direct customers and generates annual revenues estimated between $300–400 million, with gross margins typical of direct-to-consumer supplement brands (55–70%). The acquisition price—$3.8 billion for a company with sub-$400 million revenue—implies a revenue multiple of approximately 9–13x, which is high relative to traditional supplement makers but consistent with valuations of high-touch, data-driven wellness businesses. Thorne's competitive advantage rests partly on its proprietary microbiome testing, genetic nutrient assessment, and personalized supplement protocols—services that command premium pricing and build long-term customer relationships. ## Beyond the Headline: Industry Consolidation Accelerates This deal does not exist in isolation. The dietary supplement industry has experienced unprecedented merger-and-acquisition activity over the past five years. Nestlé acquired Atrium Innovations (parent of HVMN and Orgain) for $2.6 billion in 2021. Unilever bought Liquid IV's parent company for approximately $1 billion. Nature's Bounty has acquired dozens of smaller brands. P&G's entry—one of the world's largest CPG firms, with $80+ billion in annual revenue—signals that major conglomerates now view dietary supplements not as niche or speculative, but as a core strategic category. The move also reflects demographic shifts: millennial and Gen Z consumers are more willing than their parents to invest in preventive health, and they trust clinically transparent brands over generic mass-market multivitamins. Thorne has long positioned itself as the "science first" alternative to less-rigorous supplement makers. The company publishes research on PubMed, maintains a scientific advisory board of university-affiliated researchers, and publishes its testing protocols publicly—a rare transparency posture in an industry rife with unverified claims. P&G likely acquired Thorne because its reputation and customer base provide a defensible competitive advantage in a market vulnerable to regulatory scrutiny and consumer skepticism. ## What This Means for Consumers For existing Thorne customers, the immediate implication is continuity with uncertainty. P&G has promised to maintain Thorne's independence and brand identity, but integration with P&G's supply chain, manufacturing, and sales infrastructure is inevitable. Consumers should monitor three specific shifts: (1) **Pricing**—P&G may leverage its scale to lower costs, or may raise prices to recapture acquisition costs; (2) **Product availability**—some Thorne SKUs may be discontinued while others expand; and (3) **Third-party testing standards**—P&G will need to sustain Thorne's costly third-party certification practices (NSF Certified for Sport, USP verification) to justify premium pricing and retain customers. For consumers in the broader market, the acquisition underscores that supplement quality varies dramatically. A Thorne product backed by published research and third-party testing is fundamentally different from a bottom-shelf multivitamin at a drugstore. When considering a dietary supplement for a specific health goal—whether immune support, metabolic health, or athletic recovery—the Thorne case illustrates why sourcing from brands with transparent testing and published science matters. Consumers should ask three critical questions: Does the company publish research on PubMed or in peer-reviewed journals? Are ingredients third-party tested by independent labs? Is the product NSF Certified for Sport or USP verified? These markers are rare and expensive, which is why Thorne commanded a premium valuation in the acquisition. ## What to Watch Next The acquisition is expected to close in mid-2025, pending regulatory clearance. Key milestones to monitor include: **Regulatory approval.** The Federal Trade Commission is unlikely to challenge the deal, given that P&G does not yet own a major supplement brand. However, regulators may scrutinize the move if it is part of a broader consolidation wave. **Integration announcements.** P&G's first earnings call as owner of Thorne will disclose integration plans, customer retention rates, and whether Thorne's brand momentum is sustained under new ownership. **Distribution expansion.** Watch whether P&G launches a unified wellness platform combining Thorne's testing and personalization services with P&G's scale in retail distribution—particularly availability in Target, Walmart, and Amazon, which would significantly increase Thorne's accessibility beyond its direct-to-consumer base. **Clinical pipeline advancement.** Thorne has several clinical trials ongoing. P&G's resources and regulatory expertise could accelerate commercialization of study-backed formulations, bringing new products to market faster than Thorne could independently. The supplement industry may see further consolidation in response to P&G's move. Smaller premium brands, venture-backed wellness startups, and mid-market supplement makers may become acquisition targets for other large CPG, pharmaceutical, or healthcare companies seeking credibility and scale in the high-growth wellness segment. ## Sources - [Procter & Gamble Agrees to Buy Thorne for $3.8 Billion](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQET7_2T1LJ8-TTJKT_cjI6mNS9c9wVjFkeCmULm7ay-6W7LSr0poA5za9Jq07L0CW4nv9B9-vf8auwnj-gh9lvhGv2AHYwrIhHTNIHBIPTN0qqq7dE7gHnG5QkV4hdi) — Nutraceuticals World - [P&G to acquire Thorne in premium wellness play](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNdd3XgymUad900ide9WtMcKbib_XcrNDmWwpkTuybwJoz61FWwO3iBZjtp4KrLtZCj8HapNRBvWzYlQ1jHMn1DkcLICG47gImzbfhF34SaHK8sX1QuPuylJtq) — NutraIngredients-USA.com --- *This article was researched and drafted with [Claude AI](https://claude.com) (Anthropic) and Google Gemini, and reviewed by an editor before publication. See our [editorial policy](https://dietarysupplement.ai/about/editorial-policy/).* *Disclaimer: This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, stopping, or combining supplements. These statements have not been evaluated by the FDA.*